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INTRODUCTION
Drug-induced liver injury (DILI) secondary to herbal and dietary
supplements present with unique diagnostic challenges with
potentially devastating clinical outcomes if left untreated. We
present a case of biopsy confirmed drug induced liver injury
secondary to ningxia wolfberry puree. To our knowledge, this is the
first case report in literature.

CLINICAL CASE
A 60-year-old female with no prior medical history presented to an
outpatient clinic for evaluation of jaundice, pruritis, and a cutaneous
rash. Patient was not previously taking any prescription medications and
the only recent change was the addition of a new supplement containing
ningxia wolfberry puree 6 weeks prior. Liver enzymes were elevated in a
mixed pattern. Patient underwent a chronic liver disease work up that
was negative including viral, autoimmune, and metabolic etiologies.
MRCP demonstrated no common bile duct dilation or biliary obstruction.
Liver biopsy demonstrated intracanalicular cholestasis and lobular
inflammation (image 1). Liver enzymes continued to up-trend despite
stopping the supplement. At which point she was started on prednisone
with a subsequent taper. Liver enzymes normalized over the course of 5
weeks. A 3-month follow up after treatment and maintained supplement
discontinuation demonstrated continued normal liver enzymes.
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3) Prior to initiation of
Prednisone

Total Bilirubin (mg/dL)

0.6

Total Bilirubin (mg/dL)

4.2

DISCUSSION

AST (Units/L)

18

AST (Units/L)

579

ALT (Units/L)

28

ALT (Units/L)

1484

Alkaline phosphatase (Units/L) 71

Alkaline phosphatase (Units/L)

247

2) Labs at time of Liver Biopsy

4) Labs after recovery

Total Bilirubin (mg/dL)

8.3

Total Bilirubin (mg/dL)

0.2

AST (Units/L)

147

AST (Units/L)

20

ALT (Units/L)

375

ALT (Units/L)

36

Alkaline phosphatase (Units/L)

87

The growth of over-the-counter supplement use has begun to present
diagnostic challenges of identifying accurate diagnosis and management.
While prescription medications undergo scrutinous review, most dietary and
herbal supplements are classified as a food product. Therefore, the Food
and Drug Administration does not require provisional review for safety. The
worldwide incidence of DILI reported as 19 per 100,000 with 16 percent
attributed to dietary supplements. In addition, DILI secondary to
supplements accounts for 11% of acute liver failure cases overall, with a
mortality rate of 8% and 2% requiring a transplantation. Even with prompt
diagnosis and management, studies have demonstrated 14% of individuals
will have continued liver test abnormalities beyond 6 months. While
discontinuation of the offending agent is typically sufficient, more severe
cases require further treatment with prednisone for drug induced
immunogenic injury. While many supplements are advertised as having
antioxidant and immunomodulatory activity, many of these may contain
ingredients that have strong biological effects with unclear acute and
chronic risks. Our case demonstrates primary management with prednisone
can lead to favorable outcomes with long-term liver function normalization.
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